好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Use and Complications of Pharmacologic VTE Prophylaxis in Intracerebral Hemorrhage Patients
Neuro Trauma, Critical Care, and Sports Neurology
P3 - Poster Session 3 (5:30 PM-6:30 PM)
4-004

Our objective was to determine frequency of use of pharmacologic venous VTE prophylaxis in our ICH population, occurrence of DVT / PE, and whether there was an increase in ICH volume.

Despite American Heart / American Stroke Association recommendations, use of pharmacologic venous thromboembolism (VTE) prophylaxis in intracerebral hemorrhage (ICH) patients to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) remains low.

Medical records were retrospectively reviewed for patients discharged from two urban medical facilities with a primary diagnosis of ICH between January 2016 and May 2018. Records were reviewed for patient administration of pharmacologic and mechanical VTE prophylaxis, occurrence of DVT or PE, and increase in hemorrhage volume. Descriptive statistics were reported.

Medical records were reviewed for 435 patients. Those patients who transferred or were made comfort care within 48 hours of arrival were excluded. Of the 357 patients included in the analysis, 50.1% (n=179) were male and mean age was 66.7 (±15.9). Pharmacologic prophylaxis was administered to 28% (n=100) of patients, and 72% (n=257) received mechanical only. None of these patients were reported to have had a DVT or PE. Additionally, no patients were reported to have had an increase in hemorrhagic volume.

We did not observe any increase in ICH with our patients treated with pharmacologic VTE prophylaxis in patients with ICH consistent with other’s findings.  Although we found no DVTs in the patients without pharmacologic VTE prophylaxis, our data continues to support recommendations for early pharmacologic VTE prophylaxis in ICH patients.  This data also supports need for randomized controlled study.
Authors/Disclosures
John Zurasky, MD (Providence)
PRESENTER
Dr. Zurasky has nothing to disclose.
Tamela Stuchiner (Providence Brain and Spine Institute) Ms. Stuchiner has nothing to disclose.
Katherine L. Berry, MD No disclosure on file
Elizabeth A. Baraban, PhD, MPH (Providence Health and Services) The institution of Dr. Baraban has received research support from Boehringer Ingelheim.